Cohance Lifesciences Ltd.
COHANCEHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
17 transcript(s)/analyst meet(s) served; 3 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 17 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20220513 | 2022-03-31 | yes | |
| ANALYST_MEET | 20220608 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220816 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221115 | 2022-09-30 | yes | |
| TRANSCRIPT | 20221230 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230213 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230602 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230814 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231114 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240209 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240604 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240814 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241117 | 2024-09-30 | yes | |
| DUPLICATE | 20241117 | 2024-09-30 | no | |
| TRANSCRIPT | 20241213 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250218 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250602 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250819 | 2025-06-30 | yes | |
| DUPLICATE | 20250819 | 2025-06-30 | no | |
| TRANSCRIPT | 20251101 | 2025-09-30 | yes | |
| TRANSCRIPT | 20251117 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260515 | 2026-03-31 | yes | |
| DUPLICATE | 20260515 | 2026-03-31 | no | |
| TRANSCRIPT | 20260811 | 2026-06-30 | yes |
COHANCE
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
The closes are adjusted for every split and bonus on record inside the period this series covers, and each adjustment is checked against the price move on its ex-date.
| Last close | 454.15 |
| 52-week range | 279.9 – 904.75 |
| Return 1M | 1.96% |
| Return 3M | -0.85% |
| Return 1Y | -49.43% |
| Return 3Y | -13.85% |
| Return 5Y | -15.97% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 422.00 |
| Other income | 12.00 |
| Total income | 435.00 |
| Cost of materials consumed | 159.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | -38.00 |
| Employee benefit expense | 133.00 |
| Finance costs | 7.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.57 | 0.00 |
| institutions foreign | 0.07 | 0.01 |
| institutions domestic | 0.20 | -0.02 |
| mutual funds | 0.18 | -0.00 |
| public | 0.43 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| ANALYST_MEET | 2022-03-31 | 1 |
| DUPLICATE | 2026-03-31 | 3 |
| TRANSCRIPT | 2026-06-30 | 20 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 364.00 | 339.00 | 278.00 | 354.00 | 369.00 | 348.00 | 231.00 | 220.00 | 231.00 | 258.00 | 307.00 | 549.00 | 556.00 | 545.00 | 619.00 | 422.00 |
| Other income | 17.00 | 11.00 | 11.00 | 13.00 | 11.00 | 11.00 | 20.00 | 14.00 | 18.00 | 14.00 | 16.00 | 14.00 | 16.00 | 6.00 | -2.00 | 12.00 |
| Total income | 381.00 | 350.00 | 289.00 | 367.00 | 381.00 | 358.00 | 251.00 | 234.00 | 249.00 | 272.00 | 323.00 | 563.00 | 571.00 | 551.00 | 617.00 | 435.00 |
| Cost of materials consumed | 130.00 | 113.00 | 86.00 | 136.00 | 96.00 | 80.00 | 51.00 | 64.00 | 38.00 | 47.00 | 67.00 | 178.00 | 192.00 | 196.00 | 139.00 | 159.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -20.00 | -16.00 | 0.00 | -26.00 | 21.00 | 21.00 | 6.00 | 9.00 | 25.00 | 5.00 | -11.00 | -30.00 | -50.00 | -38.00 | 75.00 | -38.00 |
| Employee benefit expense | 31.00 | 27.00 | 29.00 | 30.00 | 26.00 | 29.00 | 29.00 | 33.00 | 46.00 | 52.00 | 63.00 | 133.00 | 127.00 | 119.00 | 129.00 | 133.00 |
| Finance costs | 2.00 | 1.00 | 0.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 3.00 | 10.00 | 9.00 | 9.00 | 9.00 | 7.00 |
| Depreciation and amortisation | 10.00 | 12.00 | 12.00 | 12.00 | 12.00 | 13.00 | 12.00 | 13.00 | 13.00 | 17.00 | 20.00 | 45.00 | 44.00 | 47.00 | 51.00 | 50.00 |
| Other expenses | 65.00 | 64.00 | 64.00 | 68.00 | 58.00 | 51.00 | 47.00 | 49.00 | 42.00 | 50.00 | 71.00 | 156.00 | 167.00 | 172.00 | 177.00 | 168.00 |
| Total expenses | 219.00 | 201.00 | 191.00 | 221.00 | 215.00 | 194.00 | 145.00 | 169.00 | 166.00 | 172.00 | 213.00 | 493.00 | 487.00 | 505.00 | 581.00 | 477.00 |
| Profit before exceptional items and tax | 161.00 | 149.00 | 98.00 | 146.00 | 166.00 | 164.00 | 105.00 | 65.00 | 83.00 | 100.00 | 110.00 | 71.00 | 84.00 | 45.00 | 36.00 | -43.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.00 | 0.00 | -5.00 | -17.00 | 0.00 |
| Profit before tax | 161.00 | 149.00 | 98.00 | 146.00 | 166.00 | 164.00 | 105.00 | 65.00 | 83.00 | 100.00 | 110.00 | 63.00 | 84.00 | 41.00 | 20.00 | -43.00 |
| Current tax | 60.00 | 41.00 | 25.00 | 38.00 | 41.00 | 41.00 | 24.00 | 15.00 | 20.00 | 28.00 | 42.00 | 18.00 | 27.00 | 12.00 | 22.00 | 2.00 |
| Deferred tax | 10.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 4.00 | 2.00 | -10.00 | -15.00 | -2.00 | -10.00 | -1.00 | -11.00 | 0.00 |
| Tax expense | 70.00 | 41.00 | 26.00 | 38.00 | 42.00 | 43.00 | 26.00 | 19.00 | 22.00 | 18.00 | 26.00 | 16.00 | 17.00 | 12.00 | 12.00 | 2.00 |
| Profit for the period | 92.00 | 108.00 | 72.00 | 108.00 | 124.00 | 121.00 | 80.00 | 47.00 | 61.00 | 82.00 | 83.00 | 46.00 | 66.00 | 29.00 | 8.00 | -45.00 |
| Profit attributable to owners | 0.00 | 0.00 | — | 0.00 | — | 0.00 | — | — | 0.00 | 82.00 | 83.00 | 49.00 | 74.00 | 37.00 | 20.00 | -24.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | — | 0.00 | — | 0.00 | — | — | 0.00 | -0.00 | 0.00 | -2.00 | -8.00 | -8.00 | -11.00 | -21.00 |
| Other comprehensive income | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 1.00 | -0.00 | 3.00 | -0.00 | 6.00 | 7.00 | 86.00 | 6.00 |
| Total comprehensive income | 92.00 | 107.00 | 72.00 | 108.00 | 124.00 | 121.00 | 80.00 | 46.00 | 61.00 | 82.00 | 86.00 | 46.00 | 72.00 | 36.00 | 94.00 | -39.00 |
| Earnings per share, basic | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.39 | 3.23 | 3.26 | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 |
| Earnings per share, diluted | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.39 | 3.21 | 3.23 | 1.27 | 1.93 | 0.96 | 0.50 | -0.65 |
Annual results, as filed
| Line | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2026-03-31 |
|---|---|---|---|---|---|
| Revenue from operations | 834.00 | 1,010.00 | 1,320.00 | 1,340.00 | 2,269.00 |
| Other income | 18.00 | 14.00 | 92.00 | 46.00 | 34.00 |
| Total income | 852.00 | 1,024.00 | 1,413.00 | 1,387.00 | 2,303.00 |
| Cost of materials consumed | 240.00 | 310.00 | 459.00 | 430.00 | 705.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -11.00 | -8.00 | -60.00 | -21.00 | -43.00 |
| Employee benefit expense | 74.00 | 76.00 | 100.00 | 111.00 | 508.00 |
| Finance costs | 23.00 | 9.00 | 6.00 | 5.00 | 37.00 |
| Depreciation and amortisation | 24.00 | 32.00 | 39.00 | 48.00 | 187.00 |
| Other expenses | 146.00 | 191.00 | 241.00 | 254.00 | 671.00 |
| Total expenses | 496.00 | 610.00 | 786.00 | 827.00 | 2,066.00 |
| Profit before exceptional items and tax | 356.00 | 414.00 | 626.00 | 560.00 | 237.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | -29.00 |
| Profit before tax | 356.00 | 414.00 | 626.00 | 560.00 | 207.00 |
| Current tax | 89.00 | 102.00 | 190.00 | 144.00 | 80.00 |
| Deferred tax | -1.00 | 4.00 | 23.00 | 4.00 | -23.00 |
| Tax expense | 88.00 | 105.00 | 214.00 | 148.00 | 57.00 |
| Profit for the period | 317.00 | 362.00 | 454.00 | 411.00 | 150.00 |
| Profit attributable to owners | — | — | 0.00 | — | 179.00 |
| Profit attributable to non-controlling interests | — | — | 0.00 | — | -29.00 |
| Other comprehensive income | -1.00 | -1.00 | -1.00 | -0.00 | 99.00 |
| Total comprehensive income | 316.00 | 362.00 | 453.00 | 411.00 | 249.00 |
| Earnings per share, basic | 24.91 | 14.23 | 17.83 | 16.16 | 4.69 |
| Earnings per share, diluted | 24.91 | 14.23 | 17.83 | 16.16 | 4.68 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|
| Total assets | 1,806.00 | 1,966.00 | 2,120.00 | 2,506.00 | 5,568.00 | 5,730.00 |
| Non-current assets | 884.00 | 955.00 | 951.00 | 1,324.00 | 3,723.00 | 3,902.00 |
| Current assets | 922.00 | 1,011.00 | 1,169.00 | 1,147.00 | 1,809.00 | 1,796.00 |
| Property, plant and equipment | 591.00 | 584.00 | 572.00 | 652.00 | 1,763.00 | 1,990.00 |
| Capital work-in-progress | 87.00 | 165.00 | 172.00 | 241.00 | 357.00 | 173.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 214.00 | 1,255.00 | 1,284.00 |
| Other intangible assets | 79.00 | 79.00 | 79.00 | 58.00 | 95.00 | 95.00 |
| Inventories | 318.00 | 313.00 | 271.00 | 215.00 | 593.00 | 562.00 |
| Trade receivables | 111.00 | 111.00 | 137.00 | 184.00 | 590.00 | 681.00 |
| Cash and cash equivalents | 67.00 | 65.00 | 58.00 | 37.00 | 83.00 | 49.00 |
| Total equity and liabilities | 1,806.00 | 1,966.00 | 2,120.00 | 2,506.00 | 5,568.00 | 5,730.00 |
| Equity | 1,503.00 | 1,735.00 | 1,935.00 | 2,028.00 | 3,925.00 | 4,034.00 |
| Equity share capital | 25.00 | 25.00 | 25.00 | 25.00 | 38.00 | 38.00 |
| Other equity | 1,478.00 | 1,710.00 | 1,910.00 | 1,953.00 | 3,749.00 | 3,873.00 |
| Total liabilities | 303.00 | 231.00 | 184.00 | 477.00 | 1,644.00 | 1,696.00 |
| Non-current liabilities | 86.00 | 72.00 | 72.00 | 239.00 | 1,012.00 | 1,050.00 |
| Current liabilities | 216.00 | 159.00 | 112.00 | 238.00 | 631.00 | 646.00 |
| Borrowings, non-current | 20.00 | 5.00 | 0.00 | 7.00 | 73.00 | 50.00 |
| Borrowings, current | 70.00 | 65.00 | 49.00 | 2.00 | 149.00 | 119.00 |
| Trade payables | 86.00 | 65.00 | 43.00 | 65.00 | 313.00 | 285.00 |
Cash flow, as filed
| Line | 2021-09-30 | 2022-03-31 | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 123.00 | 330.00 | 416.00 | 451.00 | 252.00 | 178.00 | 261.00 | 368.00 |
| Net cash from investing activities | -71.00 | -136.00 | -183.00 | -195.00 | -238.00 | -142.00 | -194.00 | -255.00 |
| Net cash from financing activities | -41.00 | -156.00 | -211.00 | -236.00 | -22.00 | -46.00 | -83.00 | -165.00 |
| Purchase of property, plant and equipment | 42.00 | 75.00 | 194.00 | 286.00 | 27.00 | 0.00 | 90.00 | 220.00 |
| Net increase in cash | 17.00 | 37.00 | 22.00 | 20.00 | -7.00 | -10.00 | -14.00 | -48.00 |
| con:CFO.BEFORE_TAX | 182.00 | 514.00 | 476.00 | 617.00 | 335.00 | 215.00 | 322.00 | 436.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | -3.00 | -6.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 59.00 | 184.00 | 57.00 | 146.00 | 65.00 | 37.00 | 61.00 | 68.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | -15.00 | -17.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -69.00 | 0.00 | 21.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 5.00 | -244.00 | 0.00 | 0.00 | 0.00 | 257.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-05-09 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 60.00 | 60.00 | 60.00 | 50.10 | 50.10 | 50.10 | 50.10 | 50.10 | 66.41 | 66.41 | 0.57 | 0.57 | 0.57 | 0.57 |
| Domestic institutions | 10.62 | 14.14 | 15.94 | 17.24 | 17.42 | 16.94 | 16.68 | 16.60 | 11.02 | 11.40 | 0.21 | 0.22 | 0.22 | 0.20 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 8.90 | 0.16 | 0.17 | 0.19 | 0.18 |
| Insurance companies | 0.11 | 1.38 | 1.89 | 1.57 | 2.09 | 2.53 | 3.20 | 3.26 | 2.17 | 2.27 | 0.04 | 0.04 | 0.03 | 0.02 |
| Foreign institutions | 9.50 | 10.01 | 10.14 | 9.54 | 9.80 | 10.70 | 10.84 | 11.05 | 7.38 | 7.23 | 0.07 | 0.06 | 0.06 | 0.07 |
| Government | — | — | — | — | — | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 40.00 | 40.00 | 40.00 | 49.90 | 49.90 | 49.90 | 49.90 | 49.90 | 33.59 | 33.59 | 0.43 | 0.43 | 0.43 | 0.43 |
| Non-institutional | 19.87 | 15.84 | 13.91 | 23.10 | 22.67 | 22.25 | 22.37 | 22.23 | 15.18 | 14.95 | 0.15 | 0.15 | 0.15 | 0.16 |
| Shares outstanding | 254564956 | 254564956 | 254564956 | 254564956 | 254564956 | 254564956 | 254564956 | 254564956 | 382567140 | 382567140 | 382567140 | 382567140 | 382567140 | 382567140 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Mr.Annaswamy Vaidheesh (till September 19, 2024) | Key management personnel | Remuneration | 29,800,000.00 | 1 |
| Mr.Sudhir Kumar Singh | Key management personnel | Remuneration | 23,100,000.00 | 1 |
| Mr.Himanshu Agarwal | Key management personnel | Remuneration | 20,600,000.00 | 1 |
| Sapala Co Ltd, Japan | Enterprise over which KMP have sig | Purchase of goods or services, Sale of goods or serv | 18,900,000.00 | 2 |
| Mr.Vivek Sharma(w.e.f September 20, 2024) | Key management personnel | Remuneration | 13,600,000.00 | 1 |
| Cohance lifesciences limited | Common Promoter | Any other transaction, Sale of goods or services | 9,900,000.00 | 5 |
| Casper pharma private limited | Wholly Owned Subsidiary | Any other transaction, Sale of goods or services | 6,900,000.00 | 2 |
| Rasayan Inc | Shareholder | Purchase of goods or services | 3,800,000.00 | 1 |
| Dr. Paidi Yella Reddy (Director) | Key management personnel | Remuneration | 3,700,000.00 | 1 |
| Sampada Laboratories Pvt Ltd | Enterprise over which KMP have sig | Any other transaction | 3,400,000.00 | 3 |
| Mr.Vinod Rao | Key management personnel | Any other transaction | 1,500,000.00 | 1 |
| Mr.Kumarapuram Gopalakrishnan Ananthakrishnan | Key management personnel | Any other transaction | 1,500,000.00 | 1 |
| Mrs.Matangi Gowrishankar | Key management personnel | Any other transaction | 1,500,000.00 | 1 |
| Mr.Pravin Udhyavara Bhadya Rao | Key management personnel | Any other transaction | 1,500,000.00 | 1 |
| Mr.Kundan Kumar Jha | Key management personnel | Remuneration | 1,000,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-05-15 | Q4FY26 | Read the call | |
| 2025-08-19 | Q1FY26 | Read the call | |
| 2025-06-02 | Q4FY25 | Read the call | |
| 2025-02-18 | Q3FY25 | Read the call | |
| 2024-11-17 | Q2FY25 | Read the call | |
| 2024-08-14 | Q1FY25 | Read the call | |
| 2024-06-04 | Q4FY24 | Read the call | |
| 2024-02-09 | Q3FY24 | Read the call | |
| 2023-11-14 | Q2FY24 | Read the call | |
| 2023-08-14 | Q1FY24 | Read the call | |
| 2023-06-02 | Q4FY23 | Read the call | |
| 2023-02-13 | Q3FY23 | Read the call | |
| 2022-12-30 | Q2FY23 | Read the call | |
| 2022-11-15 | Q2FY23 | Read the call | |
| 2022-08-16 | Q1FY23 | Read the call | |
| 2022-05-13 | Q4FY22 | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q3FY23 | Q3FY24 | Q3FY25 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | And right now, I don't need any capital expenditure for the Casper. | Talking about near-term weakness, so, what's your CAPEX plan, are we putting that on hold, or we want to continue with that, if you can throw light on… | You are aware that we have given a growth CAPEX to NJ Bio and we are keen to kind of create a commercial facility in New Jersey to accelerate the grow… | So, is there any other plans to utilize this cash apart from the normal capex that we would be doing in Suven Pharma? | 285 crore on capex in FY23, can you please elaborate in terms of what was the areas where we spent this capex on? | So what kind of investment are you looking in terms of capex to have that kind of a revenue? | 314 crore of CAPEX that is there on the Pro forma P&L for FY '25. | — |
| Capital allocation | — | — | My question pertains to the NJ Bio Pharma acquisition. | On your Casper acquisition, can you share what is the outlook here, what is your plan going forward with this facility, what kind of product are you f… | My second question is on the acquisition and merger process, where are we currently in this process related to the tender and related to the acquisiti… | I would like to know whether along with the acquisition of Suven Pharma; Casper Pharma is also being acquired by Advent, am I right? | Rationale for acquisition of Sapala and NJ Bio, I think we have been consistently saying as a tech, as CEO, we wanted to expand our capabilities on te… | — |
| Costs | — | — | We might end up supplying some of the very basic raw materials to them, yet it can be commercial. | On gross margins, we are also seeing inflationary pressure on the raw material prices. | The only reason is not able to have the things and get the raw material somewhere else and high prices and suddenly sometimes it may affect it, but in… | — | — | — |
| Debt and cash | — | — | My second question is on the working capital. | Because we'll be obviously generating another Rs.350, 400 crore kind of operating cash this year itself, so you just want to kind of pile up on the ex… | — | Because normally we state positive figure as net debt. | — | — |
| Demand | But any number of late stage products we have in the pipeline? | Just to let you know, as you understand the kind of innovative customer that we deal with, we are abide by certain NDAs and we prefer not to dwell on … | So, our strategic intent of lateral is also expanding the pipeline. | Firstly, since we have completed this Casper Pharma's acquisition, could you talk a little bit about the opportunity over here, like what is the end m… | And the second question on the CDMO Pharma, so if you can give your pipeline for Phase-3 and Phase-2 molecules? | Are the inquiries related to more developmental projects which are in earlier phases or is it more related to Phase 2 and Phase 3 pipeline? | Abdulji, at the current stage, we can only share with you that the Phase-3 pipeline has actually grown healthy. | I think what we must understand, and I think I mentioned that to Kartik, that there is a large commercial which got dropped in the FY26. And as you kn… |
| Guidance | I think the long-term growth prospects are very good and we expect that to benefit us in the long run, especially with the China Plus One or China Min… | We are seeing that given the global situation starting right now, we expect the next few quarters to be soft. | And therefore we expect the demand to come back shortly. | So, as it is, this was a good growth last year compared to the year before and we hope to maintain the same plus around 10% to 15% growth as of now th… | We expect more 7 or 8 approvals during this year and that will add to revenue eventually. | I think Dr. Prasada has also mentioned in various communications that we are investing in the business and we continue to invest in the business becau… | And, into your guidance for next year of double-digit growth, so just wanted to understand what would be the key growth drivers, including your Pharma… | One is if you could for FY26, that is split the CDMO revenues into ADCs, small molecules, Sapala, and NJ and give an outlook for '27 and beyond? |
| Margin | At the same time, the EBITDA is less by about Rs. | Can you help us understand what this adjusted EBITDA, I mean, the old inventory provision that you have kind of provided in the recent presentation? | — | But that would be slightly lower than FY22, right, if you're saying 40% EBITDA margin then? | Despite this our gross margin on a YoY basis and on a quarter- on-quarter basis contracted and our EBITDA margin is high because there is a lower cost… | In the fourth quarter, gross margins have improved, but your EBITDA margins are down. | Does that continue to remain for some more time, and which is why the EBITDA margin dragged down? | And the first half is weak with quarter 1 in particular weak with both revenue and EBITDA. |
| People | So, can you just give an update on the Casper facility, which you acquired last year and whether your contract to increase the capacity utilization ov… | So again, this is an ongoing exercise of current capacity utilization in the case of various units of Suven that we have. | — | — | — | — | — | — |
| Pricing | — | — | — | — | So, I do not see any difference on that it will not affect anything because what we are saying is what we are giving is the number of steps we do, the… | So I'm just talking on the pricing front in the API segment. | — | — |
| Revenue growth | So, as now this thing stands, I think maybe we'll be able to come to the same number as last year, maybe a slight growth of earnings too also is a pos… | I'm just referring to your page #24 of the annual report where you had mentioned that and I quote, “The growth seems to be subdued owing to the one-of… | I would like to understand when do we start seeing that kind of acceleration in our topline? | Just because we have cash I can't go into the market and acquire no. So, the opportunity which meets the requirements, I don't want to go to a mom and… | — | Obviously, the cost is not going to grow in-line with the revenue growth. | And we keep monitoring very closely whatever is relevant which will accelerate the growth of the existing business while it becomes an additional adva… | — |